title: Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies.
authors.affiliation: Division of Cardiology, McMaster University, Hamilton General Hospital, Ontario, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Avezum
authors.forename: P
authors.initials: P
authors.lastname: Pais
authors.forename: M D
authors.initials: MD
authors.lastname: Flather
authors.forename: S
authors.initials: S
authors.lastname: Anand
authors.forename: S
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents